Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Analysis of CD39 immunostaining intensity by study group

From: Is the purinergic pathway involved in the pathology of COPD? Decreased lung CD39 expression at initial stages of COPD

CD39 Stain Score for lung parenchyma COPD NOS NS
+++ 1 (6,66) 0 (0) 1 (8,33)
++ 3 (20) 8 (61,53) 6 (50)
+ 10 (66,66) 4 (30,78) 4 (33,33)
0 1 (6,66) 1 (7,69) 1 (8,33)
Total of Samples 15 13 12
CD39 Stain Score for the Bronchi COPD NOS NS
+++ 5 (12,82) 16 (25,4) 25 (40,32)
++ 9 (23,08) 30 (47,62) 29 (46,77)
+ 21 (53,84) 17 (26,98) 8 (12,9)
0 4 (10,25) 0 (0) 0 (0)
Total of Bronchus 39 63 62
Total of Samples 12 12 12
CD39 Stain Score for the Muscular Pulmonary Artery COPD NOS NS
+++ 20 (9,13) 7 (4,46) 19 (17,59)
++ 38 (17,35) 52 (33,12) 39 (36,11)
+ 80 (36,53) 58 (36,94) 43 (39,81)
0 81 (36,98) 40 (25,48) 7 (6,48)
Total of Pulmonary Artery 219 157 108
Total of Samples 15 13 12
  1. COPD Chronic Obstructive Pulmonary Disease, NOS Non-obstructed smokers, NS Never smokers. Number of samples, Stain Intensity and Percentage are shown for each result